Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine Inc (NASDAQ: EDIT), a leader in CRISPR-based genome editing, provides this centralized hub for tracking all corporate developments and scientific advancements. Access real-time updates on clinical trial progress, regulatory milestones, and financial disclosures essential for monitoring this pioneering biotech firm.
This resource aggregates EDIT's press releases, partnership announcements, and peer-reviewed research findings. Investors will find critical updates on pipeline therapies for genetic disorders, while analysts gain insights into strategic initiatives shaping the genomic medicine landscape. Content spans quarterly earnings, intellectual property developments, and preclinical breakthroughs.
Key categories include therapy authorization updates, collaboration agreements with research institutions, and presentations at major medical conferences. All materials are sourced directly from Editas Medicine and verified financial filings to ensure reliability.
Bookmark this page for efficient tracking of EDIT's progress in developing CRISPR/Cas9 and Cas12a therapies. Check regularly for authoritative updates on one of biotech's most innovative gene-editing platforms.
Editas Medicine appointed Gilmore O’Neill as CEO effective June 1, 2022, with James C. Mullen as Executive Chairman. The company reported a significant milestone with the first pediatric patient dosed in the Phase 1/2 BRILLIANCE trial for EDIT-101, aimed at LCA10, and anticipates initial SCD data by year-end for EDIT-301. Preclinical data showed enhanced persistence and anti-tumor activity for EDIT-202. Financially, Editas held $566.4 million in cash and marketable securities as of March 31, 2022, with a net loss of $50.5 million for Q1 2022.
Editas Medicine (Nasdaq: EDIT) announced the acceptance of four abstracts, including three oral presentations, at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) from May 16-19, 2022. Key presentations feature preclinical data on EDIT-202, safety results from the BRILLIANCE trial of EDIT-101, and findings on EDIT-103 for treating retinal diseases. The company aims to share significant updates on its innovative gene editing technologies, reinforcing its commitment to developing transformative therapies for serious conditions.
Editas Medicine, a prominent genome editing company, will host a conference call and webcast on May 4, 2022, at 8:00 a.m. ET to discuss its first-quarter 2022 results and provide a corporate update. U.S. participants can dial 877-407-0989, while international callers should use 201-389-0921, approximately five minutes before the call. A live webcast and replay will be available on the Editas Medicine website. The company specializes in developing CRISPR-based genomic medicines aimed at treating serious diseases globally.
Editas Medicine, Inc. (Nasdaq: EDIT) received Rare Pediatric Disease designation from the FDA for EDIT-301, a gene-edited treatment for beta thalassemia, complementing its previous designation for sickle cell disease. This designation underscores the urgent need for new therapies for severe conditions affecting children. The company plans to initiate a Phase 1/2 study for EDIT-301 in 2022, potentially benefiting patients requiring lifelong transfusions. If approved, Editas could obtain a Priority Review Voucher, enhancing its future product review processes.
Editas Medicine, Inc. (Nasdaq: EDIT) appointed Dr. Gilmore O’Neill as President and CEO, effective June 1, 2022. James C. Mullen will transition to Executive Chairman. Dr. O’Neill brings nearly 20 years of experience in genetic medicine and has successfully led various clinical programs, including marketing approvals for multiple medicines. He previously served at Sarepta Therapeutics and Biogen. Mullen expressed confidence in O’Neill's leadership to drive growth and advance clinical trials, ultimately aiming to deliver transformative genomic medicines to patients.
On April 11, 2022, Editas Medicine announced the successful administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient in the BRILLIANCE clinical trial. This milestone marks the first in vivo delivery of a CRISPR gene therapy to a child, targeting Leber congenital amaurosis 10 (LCA10), a severe genetic eye disorder. The company is on track to complete dosing of the pediatric mid-dose cohort in H1 2022 and initiate high-dose dosing this year.
EDIT-101 has received FDA Rare Pediatric Disease and Orphan Drug designations, emphasizing its potential to address unmet medical needs.
Editas Medicine (Nasdaq: EDIT) announced significant preclinical data demonstrating enhanced anti-tumor activity of edited iNK cells. In combination with trastuzumab, these cells achieved complete tumor clearance in 6 out of 8 treated mice, showing increased persistence and 100% survival by day 144. The data, presented at the AACR conference, supports the potential of these cells as off-the-shelf immunotherapy for solid tumors. Mark S. Shearman, Ph.D., highlighted the promising characteristics of these engineered cells, reinforcing their capability in cancer treatment.
Editas Medicine (Nasdaq: EDIT) received a favorable decision from the U.S. Patent and Trademark Office affirming the Broad Institute's patents on CRISPR/Cas9 gene editing in human cells. This ruling concludes the U.S. patent interference case with the University of California and others, confirming Broad as the first inventor of this critical technology. The patents, exclusively licensed to Editas, underpin the development of medicines for serious diseases, including their lead program, EDIT-101, aimed at treating LCA10.
Editas Medicine (Nasdaq: EDIT) announced key developments in its gene editing pipeline on February 24, 2022. The company is progressing in its BRILLIANCE trial for EDIT-101, aiming to complete pediatric cohort dosing by mid-2022. EDIT-301 is set to begin dosing sickle cell patients in the first half of 2022, while IND-enabling studies for EDIT-202 are advancing. Financial results show a reduced net loss of $41.4 million in Q4 2021, down from $62.5 million year-over-year, despite a decline in revenue from $90.7 million in 2020 to $25.5 million in 2021. Current cash reserves are $619.9 million, expected to sustain operations through 2023.
Editas Medicine, a prominent genome editing company, will host a conference call and webcast on February 24, 2022, at 8:00 a.m. ET to discuss updates and fourth quarter and full year 2021 results. U.S. participants can join by calling 877-407-0989, while international callers should dial 201-389-0921. The event will also be available via live webcast on the company’s website. Editas focuses on using CRISPR technology to develop precision genomic medicines for serious diseases worldwide. For more details, visit Editas Medicine.